Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

KPAX002 looking promising for chronic fatigue sufferers
June 2018
SHARING OPTIONS:

MILL VALLEY, Calif.—The Synergy Trial has found KPAX002, a combination treatment comprised of methylphenidate (generic Ritalin) co-administered with a micronutrient formula that broadly supports mitochondrial function, was found to be effective in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The trial consisted of 128 individuals with moderate to severe ME/CFS, a neurodegenerative disease with no FDA-approved treatment. KPAX002 was found to be most effective in patients with more severe ME/CFS and those with both fatigue and pain. Trial participants in those groups saw more than double the level of improvement after treatment than patients receiving placebo.
 
Dr. Jon D. Kaiser, CEO of K-PAX Pharmaceuticals, which funded the study, said that “In addition to ME/CFS, there is ample research to support the assertion that Alzheimer’s and Parkinson’s diseases are also progressive mitochondrial diseases with the potential to respond to KPAX002. We are planning future clinical trials in these disease states as well.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.